TP53和CDKN2A的改变定义了淋巴结T滤泡辅助细胞淋巴瘤患者预后不良的亚组

IF 12.8 1区 医学 Q1 HEMATOLOGY
Yuta Ito, Joji Shimono, Keisuke Kawamoto, Kanako C. Hatanaka, Yasunori Kogure, Mariko Tabata, Yuki Saito, Kota Mizuno, Sara Horie, Yosuke Mizukami, Junji Koya, Koichi Murakami, Takanori Teshima, Yutaka Hatanaka, Kenichi Chiba, Ai Okada, Yuichi Shiraishi, Hiroaki Miyoshi, Yoshihiro Matsuno, Koichi Ohshima, Keisuke Kataoka, Masao Nakagawa
{"title":"TP53和CDKN2A的改变定义了淋巴结T滤泡辅助细胞淋巴瘤患者预后不良的亚组","authors":"Yuta Ito, Joji Shimono, Keisuke Kawamoto, Kanako C. Hatanaka, Yasunori Kogure, Mariko Tabata, Yuki Saito, Kota Mizuno, Sara Horie, Yosuke Mizukami, Junji Koya, Koichi Murakami, Takanori Teshima, Yutaka Hatanaka, Kenichi Chiba, Ai Okada, Yuichi Shiraishi, Hiroaki Miyoshi, Yoshihiro Matsuno, Koichi Ohshima, Keisuke Kataoka, Masao Nakagawa","doi":"10.1038/s41375-025-02631-5","DOIUrl":null,"url":null,"abstract":"<p>Nodal T follicular helper cell lymphoma (nTFHL) exhibits unique immunophenotypes and somatic alterations, while the prognostic value of these alterations remains unclear. By analyzing 173 nTFHL cases, we identified 36 driver genes, including 4 novel ones (<i>TET3</i>, <i>HLA-C</i>, <i>NRAS</i>, and <i>KLF2</i>). Then, we classified nTFHL cases into four molecular subgroups by major driver alterations. TR-I (+) and TR-I (−) were characterized by <i>TET2</i> and/or <i>RHOA</i> mutations with and without <i>IDH2</i> mutations; AC53 by <i>TP53</i> and/or <i>CDKN2A</i> alterations and aneuploidy; and NSD with no subgroup-defining alterations (namely without any of the above alterations). AC53 exhibited the worst survival, while NSD, particularly those lacking driver alterations, showed the best prognosis. nTFHL had a better prognosis than peripheral T-cell lymphoma, not otherwise specified, when <i>TP53</i> and/or <i>CDKN2A</i> alterations were absent. Multivariable analyses showed that AC53, the presence of driver alterations, and international prognostic index high-risk were independently associated with worse survival. Finally, we developed a simple prognostic index (mTFHL-PI), which classified patients into three risk categories with a median OS of 181, 67, and 20 months, respectively. Our study identifies novel prognostic factors, namely <i>TP53</i> and/or <i>CDKN2A</i> alterations and the presence of driver alterations, demonstrating the clinical relevance of molecular classification in nTFHL.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"14 1","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma\",\"authors\":\"Yuta Ito, Joji Shimono, Keisuke Kawamoto, Kanako C. Hatanaka, Yasunori Kogure, Mariko Tabata, Yuki Saito, Kota Mizuno, Sara Horie, Yosuke Mizukami, Junji Koya, Koichi Murakami, Takanori Teshima, Yutaka Hatanaka, Kenichi Chiba, Ai Okada, Yuichi Shiraishi, Hiroaki Miyoshi, Yoshihiro Matsuno, Koichi Ohshima, Keisuke Kataoka, Masao Nakagawa\",\"doi\":\"10.1038/s41375-025-02631-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Nodal T follicular helper cell lymphoma (nTFHL) exhibits unique immunophenotypes and somatic alterations, while the prognostic value of these alterations remains unclear. By analyzing 173 nTFHL cases, we identified 36 driver genes, including 4 novel ones (<i>TET3</i>, <i>HLA-C</i>, <i>NRAS</i>, and <i>KLF2</i>). Then, we classified nTFHL cases into four molecular subgroups by major driver alterations. TR-I (+) and TR-I (−) were characterized by <i>TET2</i> and/or <i>RHOA</i> mutations with and without <i>IDH2</i> mutations; AC53 by <i>TP53</i> and/or <i>CDKN2A</i> alterations and aneuploidy; and NSD with no subgroup-defining alterations (namely without any of the above alterations). AC53 exhibited the worst survival, while NSD, particularly those lacking driver alterations, showed the best prognosis. nTFHL had a better prognosis than peripheral T-cell lymphoma, not otherwise specified, when <i>TP53</i> and/or <i>CDKN2A</i> alterations were absent. Multivariable analyses showed that AC53, the presence of driver alterations, and international prognostic index high-risk were independently associated with worse survival. Finally, we developed a simple prognostic index (mTFHL-PI), which classified patients into three risk categories with a median OS of 181, 67, and 20 months, respectively. Our study identifies novel prognostic factors, namely <i>TP53</i> and/or <i>CDKN2A</i> alterations and the presence of driver alterations, demonstrating the clinical relevance of molecular classification in nTFHL.</p>\",\"PeriodicalId\":18109,\"journal\":{\"name\":\"Leukemia\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41375-025-02631-5\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41375-025-02631-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

淋巴结T滤泡辅助细胞淋巴瘤(nTFHL)表现出独特的免疫表型和体细胞改变,而这些改变的预后价值尚不清楚。通过分析173例nTFHL病例,我们鉴定出36个驱动基因,其中包括4个新基因(TET3、HLA-C、NRAS和KLF2)。然后,我们根据主要驱动因素的改变将nTFHL病例分为四个分子亚组。tr - 1(+)和tr - 1(-)以TET2和/或RHOA突变为特征,伴有或不伴有IDH2突变;AC53通过TP53和/或CDKN2A改变和非整倍体;以及没有子组定义改变的NSD(即没有上述任何改变)。AC53表现出最差的生存,而NSD,特别是缺乏驱动改变的NSD,表现出最好的预后。当TP53和/或CDKN2A改变不存在时,nTFHL的预后优于外周t细胞淋巴瘤(无其他特殊说明)。多变量分析显示,AC53、驱动因素改变的存在和国际预后指数高风险与较差的生存率独立相关。最后,我们制定了一个简单的预后指数(mTFHL-PI),将患者分为三个风险类别,中位生存期分别为181、67和20个月。我们的研究确定了新的预后因素,即TP53和/或CDKN2A的改变和驱动改变的存在,证明了nTFHL分子分类的临床相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma

TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma

Nodal T follicular helper cell lymphoma (nTFHL) exhibits unique immunophenotypes and somatic alterations, while the prognostic value of these alterations remains unclear. By analyzing 173 nTFHL cases, we identified 36 driver genes, including 4 novel ones (TET3, HLA-C, NRAS, and KLF2). Then, we classified nTFHL cases into four molecular subgroups by major driver alterations. TR-I (+) and TR-I (−) were characterized by TET2 and/or RHOA mutations with and without IDH2 mutations; AC53 by TP53 and/or CDKN2A alterations and aneuploidy; and NSD with no subgroup-defining alterations (namely without any of the above alterations). AC53 exhibited the worst survival, while NSD, particularly those lacking driver alterations, showed the best prognosis. nTFHL had a better prognosis than peripheral T-cell lymphoma, not otherwise specified, when TP53 and/or CDKN2A alterations were absent. Multivariable analyses showed that AC53, the presence of driver alterations, and international prognostic index high-risk were independently associated with worse survival. Finally, we developed a simple prognostic index (mTFHL-PI), which classified patients into three risk categories with a median OS of 181, 67, and 20 months, respectively. Our study identifies novel prognostic factors, namely TP53 and/or CDKN2A alterations and the presence of driver alterations, demonstrating the clinical relevance of molecular classification in nTFHL.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Leukemia
Leukemia 医学-血液学
CiteScore
18.10
自引率
3.50%
发文量
270
审稿时长
3-6 weeks
期刊介绍: Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信